Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Endometrial Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Endometrial Cancer (217
)
Endometrial Cancer (217
)
›
Associations
(15)
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 expression
Endometrial Adenocarcinoma
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
No biomarker
Endometrial Adenocarcinoma
No biomarker
Endometrial Adenocarcinoma
ZN-c3
Sensitive: B - Late Trials
ZN-c3
Sensitive
:
B
ZN-c3
Sensitive: B - Late Trials
ZN-c3
Sensitive
:
B
HER-2 overexpression
Endometrial Adenocarcinoma
HER-2 overexpression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
HER-2 positive
Endometrial Adenocarcinoma
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
MSI-H/dMMR
Endometrial Adenocarcinoma
MSI-H/dMMR
Endometrial Adenocarcinoma
AZD1775
Sensitive: C3 – Early Trials
AZD1775
Sensitive
:
C3
AZD1775
Sensitive: C3 – Early Trials
AZD1775
Sensitive
:
C3
HER-2 positive
Endometrial Adenocarcinoma
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C3 – Early Trials
trastuzumab
Sensitive
:
C3
trastuzumab
Sensitive: C3 – Early Trials
trastuzumab
Sensitive
:
C3
MSH2 deletion
Endometrial Adenocarcinoma
MSH2 deletion
Endometrial Adenocarcinoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
MLH1 deletion
Endometrial Adenocarcinoma
MLH1 deletion
Endometrial Adenocarcinoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
ARID1A mutation
Endometrial Adenocarcinoma
ARID1A mutation
Endometrial Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ER positive
Endometrial Adenocarcinoma
ER positive
Endometrial Adenocarcinoma
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
ER positive
Endometrial Adenocarcinoma
ER positive
Endometrial Adenocarcinoma
letrozole
Sensitive: C4 – Case Studies
letrozole
Sensitive
:
C4
letrozole
Sensitive: C4 – Case Studies
letrozole
Sensitive
:
C4
MSH6 F1088fs
Endometrial Adenocarcinoma
MSH6 F1088fs
Endometrial Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
HER-2 amplification
Endometrial Adenocarcinoma
HER-2 amplification
Endometrial Adenocarcinoma
lapatinib
Sensitive: D – Preclinical
lapatinib
Sensitive
:
D
lapatinib
Sensitive: D – Preclinical
lapatinib
Sensitive
:
D
HER-2 amplification
Endometrial Adenocarcinoma
HER-2 amplification
Endometrial Adenocarcinoma
trastuzumab + lapatinib
Sensitive: D – Preclinical
trastuzumab + lapatinib
Sensitive
:
D
trastuzumab + lapatinib
Sensitive: D – Preclinical
trastuzumab + lapatinib
Sensitive
:
D
HER-2 amplification
Endometrial Adenocarcinoma
HER-2 amplification
Endometrial Adenocarcinoma
afatinib
Sensitive: D – Preclinical
afatinib
Sensitive
:
D
afatinib
Sensitive: D – Preclinical
afatinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login